CHMP recommends EU approval of Roche’s Susvimo for neovascular AMD
The CHMP has recommended the approval of Susvimo, a continuous delivery treatment for neovascular AMD, based on positive clinical trial data.
Asset / Drug
Drug and asset intelligence for Susvimo with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.